← Patent-cliff monitor small molecule LITFULO RITLECITINIB TOSYLATE
Loss of exclusivity October 2041 latest FDA-listed patent expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name LITFULO Active ingredient RITLECITINIB TOSYLATE Strength EQ 50MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval June 2023 Marketing status RX
Listed patents Patent Expires Type 12116368 October 2041 substance 12077533 December 2034 use U-3994 9617258 December 2034 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.